Schering Corporation

Merck Sharp + Dohme Corp.

Schering-plough Corporation

Other

Pharmacopeia Drug Discovery, Inc.

Albany Molecular Research, Inc.

Schering Coporation

Scheeing Corporation

Pharmacopeia Inc.

Robert G Aslanian

Kevin D McCormick

Neng-Yang Shih

Christopher W Boyce

Michael Berlin

Anandan Palani

Pauline C Ting

Xianhai Huang

Pietro Mangiaracina

John J Piwinski

Stuart B Rosenblum

Daniel M Solomon

Manuel De Lera Ruiz

Junying Zheng

Mwangi W Mutahi

Wing C Tom

Dong Xiao

Younong Yu

Ashwin Umesh Rao

Jun Qin

Ying Huang

Jianhua Chao

Xiao Chen

Salem Fevrier

Purakkattle J Biju

Wei Zhou

Xiaohong Zhu

Jianhua Cao

Li Dong

Ning Shao

Rongze Kuang

Walter Won

Henry A Vaccaro

Phieng Siliphaivanh

Gregory A Reichard

Qingbei Zeng

Chia-Yu Huang

Bo Liang

Pawan Dhondi

Jie Wu

Ashit K Ganguly

Brian Alexander McKittrick

Hongjun Zhang

Joey Lee Methot

Robert D Mazzola, Jr

Nicolas Zorn

Henry M Vaccaro

Rong-qiang Liu

John J Baldwin

William J Greenlee

Ge Li

Duane A Burnett

Michael J Green

Ronald L Wolin

Wayne D Vaccaro

Bandarpalle B Shankar

Tin-Yau Chan

Haiqun Tang

Qin Jiang

Heping Wu

Chad E Bennett

Gang Zhou

Elizabeth Helen Kelley

Rachel Nicola MacCoss

Nicholas I Carruthers

John A Hey

Hyunjin M Kim

Michael P Kirkup

Ruiyan Liu

Joseph A Kozlowski

Zhaoning Zhu

John W Clader

Hubert B Josien

Elizabeth M Smith

Jason D Brubaker

Adriano Afonso

Joshua Close

Guoqing Li

Dmitri A Pissarnitski

Joon Jung

Jing Su

Robert Jason Herr

John W Butcher

John P Caldwell

Yeon-Hee Lim

Zhiqiang Zhao

Andrew T Lupo

Joel M Harris

Thomas A Bara

Mihirbaran Mandal

Michelle Martinez

Chad E Knutson

Troy McCracken

Mary Ann Caplen

John H Schwerdt

Hongwu Wang

Scott Peterson

Joe F Lee

Jae-Hun Kim

Huagang Lu

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: 'Z', Rand Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Aminopyrazine compounds with A2A antagonist properties

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

[object Object]

The invention provides certain quinolines and aza-quinolines of the Formula (I), and their pharmaceutically acceptable salts, wherein E, J, J, J, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ('DGAT') inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: 

Inhibitors of diacylglycerol acyltransferase

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ('DGAT') inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I). 

Bicyclic compounds as inhibitors of diacylglycerol acyltransferase

The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X, R, R, R, R, R, and Rare as herein described. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, and chronic obstructive pulmonary disorder. 

Fused tricyclic compounds for the treatment of inflammatory disorders

The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R, R, R, R, R, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction.

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators

The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: 

C20-C21 substituted glucocorticoid receptor agonists

This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).

Gamma secretase modulators

In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of &#xff;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#xff;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of chroman compounds of formula I as &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of prepaxing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.  

Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists

This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I) wherein Ris a fused bicyclic ring of the formula (II). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I). 

Growing community of inventors

Rockaway, NJ, United States of America

Robert G Aslanian